Lt3001 Podcast
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Summary
Patients with AIS and disabling symptoms often have limited treatment options, particularly when reperfusion therapies are not feasible. LT3001 (Odatroltide), a novel molecule that enhances endogenous fibrinolysis and scavenges free radicals, was evaluated in two Phase 2 trials with distinct selection strategies
adbl_web_anon_alc_button_suppression_c
No reviews yet